The report examines registration and pricing practices for specific products and countries. A key finding is more companies are making progress in setting prices reflecting the socioeconomic context, with greater use of equitable pricing strategies.
Yet performance of the pharmaceutical industry continues to lag in some areas critical to improving access. For example, whilst companies are refining their pricing strategies to improve affordability of more products, they are applying them in few countries.
The Index highlights the significant potential for the industry to make medicines more accessible.
Sign up for our quarterly updates to find out more about how our work is making healthcare products more affordable and accessible.
